Update in systemic sclerosis-associated pulmonary arterial hypertension
- 1 October 2014
- journal article
- review article
- Published by Elsevier in La Presse Médicale
- Vol. 43 (10) , e293-e304
Abstract
No abstract availableKeywords
This publication has 146 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma RegistryArthritis Care & Research, 2013
- Survival and Prognostic Factors in Systemic Sclerosis–Associated Pulmonary Hypertension: A Systematic Review and Meta‐AnalysisArthritis & Rheumatism, 2013
- Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial HypertensionCirculation: Cardiovascular Genetics, 2012
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJACC, 2009
- Autoantigens in systemic autoimmunity: critical partner in pathogenesisJournal of Internal Medicine, 2009
- Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseasesAnnals of the Rheumatic Diseases, 2008
- Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue diseaseAnnals of the Rheumatic Diseases, 2007
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007